Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

MAP2K7 anticorps (N-Term) (Fluoro550)

Cet anticorps anti-MAP2K7 Polyclonal Lapin conjugué à Fluoro550 (ABIN8011249) détecte spécifiquement MAP2K7 dans FACS. L’anticorps est réactif avec des échantillons de Humain, Souris, Rat et Singe.
N° du produit ABIN8011249
720,50 €
Plus frais de livraison 40,00 € et TVA
100 μg
Destination: France
Envoi sous 8 à 12 jours ouvrables

Aperçu rapide pour MAP2K7 anticorps (N-Term) (Fluoro550) (ABIN8011249)

Antigène

Voir toutes MAP2K7 Anticorps
MAP2K7 (Mitogen-Activated Protein Kinase Kinase 7 (MAP2K7))

Reactivité

  • 124
  • 92
  • 88
  • 24
  • 4
  • 4
  • 4
  • 4
  • 4
  • 3
  • 3
  • 2
  • 2
  • 1
Humain, Souris, Rat, Singe

Hôte

  • 136
  • 5
Lapin

Clonalité

  • 117
  • 24
Polyclonal

Conjugué

  • 50
  • 8
  • 7
  • 5
  • 5
  • 5
  • 5
  • 5
  • 5
  • 5
  • 5
  • 4
  • 3
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
Cet anticorp MAP2K7 est conjugé à/à la Fluoro550

Application

  • 95
  • 44
  • 36
  • 35
  • 26
  • 26
  • 22
  • 20
  • 16
  • 7
  • 6
  • 1
  • 1
  • 1
Flow Cytometry (FACS)
  • Épitope

    • 39
    • 24
    • 23
    • 8
    • 5
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    N-Term

    Fonction

    Anti-MEK7/MAP2K7 Antibody Fluoro550 Conjugated

    Specificité

    No cross reactivity with other proteins.

    Réactivité croisée (Details)

    No cross-reactivity with other proteins

    Homologie

    identical to the related rat,mouse sequences.

    Purification

    Immunogen affinity purified.

    Immunogène

    A synthetic peptide corresponding to a sequence at the N-terminus of human MEK7, identical to the related rat and mouse sequences.

    Isotype

    IgG
  • Indications d'application

    Flow Cytometry, Optimal dilutions should be determined by end users.

    Restrictions

    For Research Use only
  • Format

    Liquid

    Buffer

    Each vial contains 50 % glycerol, 0.9 % NaCl, 0.2 % Na2HPO4, 0.02 % Sodium azide.

    Agent conservateur

    Sodium azide

    Précaution d'utilisation

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Stock

    -20 °C

    Stockage commentaire

    At -20°C for one year from date of receipt. Avoid repeated freezing and thawing. Protect from light.

    Date de péremption

    12 months
  • Antigène

    MAP2K7 (Mitogen-Activated Protein Kinase Kinase 7 (MAP2K7))

    Autre désignation

    MAP2K7

    Sujet

    Background: MAP2K7 (Mitogen-activated protein kinase kinase 7), also known as MAP kinase kinase 7, MAPKK7, JNKK2, PRKMK7 or MKK7, is an enzyme that in humans is encoded by the MAP2K7 gene. This protein is a member of the mitogen-activated protein kinase kinase family. The MKK7 protein exists as six different isoforms with three possible N-termini (alpha, beta, and gamma isoforms) and two possible C-termini (1 and 2 isoforms). Schramek et al. (2011) showed that the doxorubicin-mediated DNA damage response in human A549 lung carcinoma cells caused rapid phosphorylation and upregulation of p53 (TP53). MKK7 knockdown reduced p53 phosphorylation, delayed p53 upregulation, and interfered with cell cycle arrest at G2/M. MKK7 was activated in primary lung tumors, and tumors with a p53 mutation showed even higher MKK7 phosphorylation. Schramek et al. (2011) concluded that MKK7 exerts its tumor suppressive function through p53.

    Gene Full Name: mitogen-activated protein kinase kinase 7

    Sequence Similarities: Belongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily.

    ID gène

    5609

    UniProt

    O14733

    Pathways

    Signalisation MAPK, Signalisation TLR, Fc-epsilon Receptor Signaling Pathway, Activation of Innate immune Response, Toll-Like Receptors Cascades, BCR Signaling
Vous êtes ici:
Chat with us!